Migraines are more than just headaches — they can be debilitating, disruptive, and emotionally draining.
If you experience frequent migraines, especially 15 or more headache days a month, you're likely familiar with the cycle of pain, recovery, and anticipation of the next attack.
That’s where eptinezumab (brand name Vyepti) comes in — a preventative migraine treatment designed to reduce the frequency and intensity of migraine attacks before they begin.
What is Eptinezumab?
Eptinezumab is a monoclonal antibody that targets CGRP (calcitonin gene-related peptide), a protein known to play a key role in the development of migraines. By blocking CGRP, eptinezumab helps interrupt the migraine process at its source, making it an effective option for long-term prevention.
Unlike some treatments that are taken daily or during migraine attacks, eptinezumab is administered once every 3 months through an IV infusion.
How Does It Work?
Eptinezumab binds to CGRP in the bloodstream, stopping it from activating receptors that cause inflammation and pain in the brain. This reduces the chance of a migraine before symptoms even begin.
Key Benefits:
- Begins working quickly — some patients see effects within a day of infusion
- Only four treatments per year
- Shown to significantly reduce migraine days per month
- Suitable for both episodic andchronic migraine sufferers
Who Should Consider Eptinezumab?
Eptinezumab may be right for you if:
- You experience frequent migraines (chronic or episodic)
- You haven’t found relief from traditional oral or injectable medications
- You want a convenient, low-frequency treatment
- You’re looking for a preventative option that does not require daily adherence
What to Expect from Treatment
Eptinezumab is administered via IV in a clinical setting and typically takes about 30 minutes. Most patients tolerate it well, with mild side effects like fatigue, nasal congestion, or mild allergic reactions being the most commonly reported.
Results from clinical trials have shown that many patients experience a reduction of up to 8 migraine days per month, depending on their baseline.
Is Eptinezumab Covered by Insurance?
Many insurance providers do cover eptinezumab, especially for patients diagnosed with chronic migraines who have tried other treatments without success. Patient assistance programs are also available through the manufacturer for eligible individuals.
Final Thoughts
If migraines are interfering with your life, relationships, or work, it may be time to consider a proactive solution. Eptinezumab offers a promising option for those seeking long-term relief and control. With just four treatments per year, you can take back your days — and your peace of mind.